Royalty Pharma plc - Ordinary Shares - Class A Forecast, price target & analysts
Royalty Pharma plc - Ordinary Shares - Class A Target price 2025 - Analyst rating & recommendation
Royalty Pharma plc - Ordinary Shares - Class A Classifications & Recommendation:
Royalty Pharma plc - Ordinary Shares - Class A Price Target
| Target Price | $40.67 |
| Price | $31.26 |
| Potential |
30.09%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Royalty Pharma plc - Ordinary Shares - Class A 2026 .
The average Royalty Pharma plc - Ordinary Shares - Class A target price is $40.67.
This is
30.09%
register free of charge
$51.00
63.15%
register free of charge
$28.00
10.43%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Royalty Pharma plc - Ordinary Shares - Class A to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Royalty Pharma plc - Ordinary Shares - Class A stock has an average upside potential 2026 of
30.09%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.35 | 2.69 |
| 5.24% | 14.19% | |
| EBITDA Margin | 63.37% | 94.80% |
| 52.69% | 49.59% | |
| Net Margin | 47.93% | 26.05% |
| 2,303.93% | 45.65% |
7 Analysts have issued a sales forecast Royalty Pharma plc - Ordinary Shares - Class A 2024 . The average Royalty Pharma plc - Ordinary Shares - Class A sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Royalty Pharma plc - Ordinary Shares - Class A EBITDA forecast 2024. The average Royalty Pharma plc - Ordinary Shares - Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Royalty Pharma plc - Ordinary Shares - Class A 2024 . The average Royalty Pharma plc - Ordinary Shares - Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.53 | 1.57 |
| 2,430.00% | 37.94% | |
| P/E | 19.91 | |
| EV/Sales | 8.88 |
1 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast for earnings per share. The average Royalty Pharma plc - Ordinary Shares - Class A <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Royalty Pharma plc - Ordinary Shares - Class A stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Royalty Pharma plc - Ordinary Shares - Class A...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
